T2 Biosystems Announces Submission for FDA Breakthrough Device Designation for Candida Auris Diagnostic Test
Company plans to add multidrug-resistant Candida auris detection to its FDA-cleared T2Candida Panel LEXINGTON, Mass.,…
Company plans to add multidrug-resistant Candida auris detection to its FDA-cleared T2Candida Panel LEXINGTON, Mass.,…
In a preclinical model of ischemic stroke, systemic delivery of a selective Fzd4 Wnt antibody…
In a preclinical model of ischemic stroke, systemic delivery of a selective Fzd4 Wnt antibody…
IRVINE, Calif., June 05, 2023 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission…
IRVINE, Calif., June 05, 2023 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission…
SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) — Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM),…
SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) — Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM),…
Qualigen Therapeutics, Inc. Co-operation between RAS-F series and AMG-510 and MRTX1133 Preclinical Data Show Potential…
Qualigen Therapeutics, Inc. Co-operation between RAS-F series and AMG-510 and MRTX1133 Preclinical Data Show Potential…
IFx-Hu2.0 demonstrated to have a promising safety profile at all 3 dose schedules tested 5…
IFx-Hu2.0 demonstrated to have a promising safety profile at all 3 dose schedules tested 5…
– Trial includes high risk AML patients that have relapsed post allo-HSCT and are refractory…
– Trial includes high risk AML patients that have relapsed post allo-HSCT and are refractory…
Clinical activity observed in multiple tumor types; longer progression-free survival observed in patients with high…
Clinical activity observed in multiple tumor types; longer progression-free survival observed in patients with high…
Media Release Efti plus pembrolizumab led to deep, durable responses, regardless of PD-L1 expression levels,…
Media Release Efti plus pembrolizumab led to deep, durable responses, regardless of PD-L1 expression levels,…
Interim data presented at ASCO show early evidence of single agent activity with meaningful reduction…
Interim data presented at ASCO show early evidence of single agent activity with meaningful reduction…
This is the second deal announced between Rani and Celltrion, building upon a previously announced…